California Sues 39 Firms For Reporting Inflated Prices To Medicaid
This article was originally published in The Pink Sheet Daily
Executive Summary
Wyeth is dropped from defendant list, but Amgen, GlaxoSmithKline, Bristol-Myers Squibb and Novartis are among firms joining original defendant Abbott.
You may also be interested in...
GSK Settlement Of AWP “Spread” Case Includes Pricing Audits
Under a settlement with the Justice Department, GlaxoSmithKline will pay $150 mil. and expand compliance program training required by an existing corporate integrity agreement.
NME Slowdown Shows Market Pressure On Me-Toos, Not FDA Caution – Lutter
DURHAM, N.C. - The decline in FDA's tally of new molecular entity approvals stems from fewer approvals of non-innovative products in recent years, while approvals of truly innovative products has largely held steady, according to FDA Deputy Commissioner for Policy, Planning and Preparedness Randall Lutter